Balyasny Asset Management’s Structure Therapeutics GPCR Stock Holding History

Balyasny Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.7M	Buy	304,934 +88,735	+41%	+$6.07M	0.02%	835
2025 Q4	$15M	Sell	216,199 -245,354	-53%	-$10M	0.02%	859
2025 Q3	$12.9M	Buy	+461,553	New	+$9.19M	0.02%	925
2025 Q2	–	Sell	-202,483	Closed	-$3.5M	–	3022
2025 Q1	$3.5M	Buy	+202,483	New	+$4.96M	0.01%	1423
2023 Q4	–	Sell	-13,430	Closed	-$677K	–	2643
2023 Q3	$677K	Buy	+13,430	New	+$433K	﹤0.01%	1665

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Balyasny Asset Management's GPCR Position: Q1 2026 in Review

Balyasny Asset Management increased its Structure Therapeutics (GPCR) stake by 41% in Q1 2026, buying an estimated $6.07M and bringing the position to 304,934 shares worth $14.7M. The position accounts for 0.02% of the portfolio, ranked #835.

Balyasny Asset Management first reported a position in GPCR in Q3 2023 and has held it in 5 quarters since. The position peaked at $15M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Balyasny Asset Management held 304,934 shares of Structure Therapeutics worth $14.7M as of Q1 2026.
Balyasny Asset Management bought 88,735 Structure Therapeutics shares in Q1 2026, an estimated $6.07M.
Structure Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #835 holding.
Balyasny Asset Management first reported a position in Structure Therapeutics in Q3 2023 and has held it in 5 quarters since.
Balyasny Asset Management's Structure Therapeutics position peaked at $15M in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.